Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | CTSA | P10619 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 6/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617115 | 1.00 | ADRA2B (0.44) | ADRA2BCTSALMNATP53MAPT | |
| SCHEMBL1616915 | 0.90 | FGFR1 (0.44) | ADRA2BCTSALMNATP53MAPT | |
| SCHEMBL1616567 | 0.90 | ADRA2B (0.48) | ADRA2BLMNATP53MAPTNPC1 | |
| SCHEMBL1615890 | 0.90 | ADRA2B (0.48) | ADRA2BLMNATP53MAPTNPC1 | |
| SCHEMBL1761634 | 0.87 | FGFR1 (0.45) | CTSALMNATP53MAPTHPGD | |
| SCHEMBL1761698 | 0.87 | FGFR1 (0.45) | CTSALMNATP53MAPTHPGD | |
| SCHEMBL1616284 | 0.85 | FGFR1 (0.45) | CTSALMNATP53MAPTHPGD | |
| SCHEMBL1761681 | 0.83 | FGFR1 (0.56) | HPGDFGFR1ALDH1A1 | |
| SCHEMBL1616093 | 0.82 | NPC1 (0.53) | LMNANPC1RAB9AHPGDFGFR1 | |
| SCHEMBL1616776 | 0.82 | NPC1 (0.53) | LMNANPC1RAB9AHPGDFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996556-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2009-11-18 | — | — | EP | claimed |
| EP-1996556-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NeuroSearch A/S (DK) | 2008-12-03 | — | — | EP | claimed |
| WO-2007065864-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-06-14 | — | — | WO | claimed |
| US-7923464-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-04-12 | — | — | US | disclosed |
| EP-1996556-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2009-11-18 | — | — | EP | disclosed |
| US-20090048321-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA-Alpha Receptor Complex | ANIONA APS (DK) | 2009-02-19 | — | — | US | disclosed |
| EP-1996556-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NeuroSearch A/S (DK) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007065864-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048321-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA-Alpha Receptor Complex | GABRB1, GABRB2, GABRB3 | ADRA2B 84/4885CTSA 2746/4885LMNA 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.